TransCode Therapeutics (RNAZ) Competitors $8.04 -0.25 (-3.02%) Closing price 07/3/2025 03:29 PM EasternExtended Trading$8.32 +0.28 (+3.48%) As of 07/3/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAZ vs. NRSN, TPST, CARA, TENX, LSTA, CYTH, FBLG, KLTO, NNVC, and BCABShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include NeuroSense Therapeutics (NRSN), Tempest Therapeutics (TPST), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Cyclo Therapeutics (CYTH), FibroBiologics (FBLG), Klotho Neurosciences (KLTO), NanoViricides (NNVC), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Its Competitors NeuroSense Therapeutics Tempest Therapeutics Cara Therapeutics Tenax Therapeutics Lisata Therapeutics Cyclo Therapeutics FibroBiologics Klotho Neurosciences NanoViricides BioAtla TransCode Therapeutics (NASDAQ:RNAZ) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment. Which has higher earnings and valuation, RNAZ or NRSN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransCode TherapeuticsN/AN/A-$16.75MN/AN/ANeuroSense TherapeuticsN/AN/A-$10.21M-$0.54-3.54 Which has more risk and volatility, RNAZ or NRSN? TransCode Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Do institutionals & insiders have more ownership in RNAZ or NRSN? 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is RNAZ or NRSN more profitable? NeuroSense Therapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TransCode TherapeuticsN/A -578.88% -222.61% NeuroSense Therapeutics N/A N/A -445.40% Do analysts rate RNAZ or NRSN? TransCode Therapeutics currently has a consensus target price of $280.00, indicating a potential upside of 3,382.59%. NeuroSense Therapeutics has a consensus target price of $14.00, indicating a potential upside of 632.98%. Given TransCode Therapeutics' higher probable upside, research analysts clearly believe TransCode Therapeutics is more favorable than NeuroSense Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media refer more to RNAZ or NRSN? In the previous week, TransCode Therapeutics and TransCode Therapeutics both had 1 articles in the media. TransCode Therapeutics' average media sentiment score of 0.00 equaled NeuroSense Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeuroSense Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryNeuroSense Therapeutics beats TransCode Therapeutics on 6 of the 8 factors compared between the two stocks. Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.04M$2.43B$5.53B$9.04BDividend YieldN/A1.78%5.24%4.02%P/E RatioN/A9.1027.5820.25Price / SalesN/A682.84417.23118.60Price / CashN/A158.5936.8958.07Price / Book-0.154.588.035.67Net Income-$16.75M$31.34M$3.18B$249.21M7 Day Performance0.88%3.25%2.91%3.28%1 Month Performance11.36%7.08%3.72%5.56%1 Year Performance-99.97%0.17%36.04%21.13% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics1.9062 of 5 stars$8.04-3.0%$280.00+3,382.6%-100.0%$7.04MN/A0.009News CoverageGap UpNRSNNeuroSense Therapeutics1.7252 of 5 stars$1.89-0.5%$14.00+640.7%+44.7%$25.97MN/A-3.5010TPSTTempest Therapeutics1.796 of 5 stars$6.80-1.4%$30.00+341.2%-74.0%$25.41MN/A-0.3820News CoverageCARACara Therapeutics0.3513 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumeTENXTenax Therapeutics1.2977 of 5 stars$5.76-1.5%$17.50+203.8%+87.4%$24.27MN/A-2.329LSTALisata Therapeutics2.519 of 5 stars$2.90+3.6%$15.00+417.2%-23.0%$24.12M$1M-1.2630Gap DownCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809FBLGFibroBiologics2.3113 of 5 stars$0.62+0.7%$13.00+1,989.4%-84.9%$23.65MN/A-2.9610Gap UpKLTOKlotho NeurosciencesN/A$1.13+56.9%N/AN/A$23.40MN/A-3.14N/AAnalyst UpgradeHigh Trading VolumeNNVCNanoViricides1.1306 of 5 stars$1.40flatN/A-20.5%$22.50MN/A-1.9420Gap UpBCABBioAtla2.5483 of 5 stars$0.40+3.1%$5.00+1,162.6%-73.4%$22.43M$11M-0.3260News CoverageGap Down Related Companies and Tools Related Companies NeuroSense Therapeutics Competitors Tempest Therapeutics Competitors Cara Therapeutics Competitors Tenax Therapeutics Competitors Lisata Therapeutics Competitors Cyclo Therapeutics Competitors FibroBiologics Competitors Klotho Neurosciences Competitors NanoViricides Competitors BioAtla Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAZ) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNAZ Stock Alerts